Neurapheresis™ for aSAH

About Pharaoh Neuro

Pharaoh Neuro is an early-stage medical device innovator targeting the high-need neurocritical care market with its Neurapheresis™ extracorporeal CSF filtration system. The company is currently conducting the PILLAR-XT clinical trial to evaluate the safety and efficacy of its platform for patients with subarachnoid hemorrhage and recently secured a $20 million Series A financing round. Led by a team with deep medtech and neurosurgical expertise, and backed by experienced founders from Minnetronix Medical, Pharaoh Neuro is positioned to advance a novel therapeutic approach for a condition with significant unmet need and catastrophic outcomes.

Therapeutic Areas